[go: up one dir, main page]

GB2448627B - Combination therapy and antibody panels - Google Patents

Combination therapy and antibody panels

Info

Publication number
GB2448627B
GB2448627B GB0812408A GB0812408A GB2448627B GB 2448627 B GB2448627 B GB 2448627B GB 0812408 A GB0812408 A GB 0812408A GB 0812408 A GB0812408 A GB 0812408A GB 2448627 B GB2448627 B GB 2448627B
Authority
GB
United Kingdom
Prior art keywords
combination therapy
antibody panels
antibody
panels
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0812408A
Other versions
GB2448627A (en
GB0812408D0 (en
Inventor
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genitope Corp
Original Assignee
Genitope Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/297,167 external-priority patent/US20070134248A1/en
Priority claimed from US11/297,168 external-priority patent/US20070134249A1/en
Application filed by Genitope Corp filed Critical Genitope Corp
Publication of GB0812408D0 publication Critical patent/GB0812408D0/en
Publication of GB2448627A publication Critical patent/GB2448627A/en
Application granted granted Critical
Publication of GB2448627B publication Critical patent/GB2448627B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GB0812408A 2005-12-08 2008-07-07 Combination therapy and antibody panels Expired - Fee Related GB2448627B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/297,167 US20070134248A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
US11/297,168 US20070134249A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
PCT/US2006/047077 WO2007067780A2 (en) 2005-12-08 2006-12-08 Combination therapy and antibody panels

Publications (3)

Publication Number Publication Date
GB0812408D0 GB0812408D0 (en) 2008-08-13
GB2448627A GB2448627A (en) 2008-10-22
GB2448627B true GB2448627B (en) 2010-07-14

Family

ID=38123554

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0812408A Expired - Fee Related GB2448627B (en) 2005-12-08 2008-07-07 Combination therapy and antibody panels

Country Status (3)

Country Link
CA (1) CA2632744A1 (en)
GB (1) GB2448627B (en)
WO (1) WO2007067780A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922212B1 (en) * 2007-10-11 2011-11-11 France Etat ANTIBODY ANTIBODY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood, Vol.88, 1996, Nelson, et al., "Tunour-specific, cytotoxic T-lymphocytes...", pp.580-589 *
Blood, Vol.92, 1998, Davis, et al., "Anti-Idiotype antibodies can induce...", pp.1184-1190 *
Haematologica, Vol.87, 2002, Ruffini, et al ., "Idiotypic vaccination for B-cell...", pp.989-1001 *

Also Published As

Publication number Publication date
GB2448627A (en) 2008-10-22
WO2007067780A3 (en) 2008-05-02
WO2007067780A2 (en) 2007-06-14
CA2632744A1 (en) 2007-06-14
GB0812408D0 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
IL184659A0 (en) Antibody variants and uses thereof
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL222922A (en) Anti-neuropilin-1 antibodies and uses thereof
HRP20140271T1 (en) Human antibodies against rabies and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL191820A0 (en) Anti-ox40l antibodies and methods using same
IL186071A0 (en) Antibodies against ccr5 and uses thereof
ZA200608100B (en) IRTA-5 antibodies and their uses
IL182554A0 (en) Anti-addl antibodies and uses thereof
SI1973950T1 (en) Anti-ephb4 antibodies and methods using the same
IL189252A0 (en) Dihydroxyanthraquinones and their use
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
IL187479A0 (en) Antigen conjugates and uses thereof
EP1838288A4 (en) Therapeutic materials and methods
EP1942911A4 (en) Therapeutic molecules and their uses
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB2448627B (en) Combination therapy and antibody panels
ZA200702281B (en) IRTA-4 antibodies and their uses
GB0505620D0 (en) Methods and materials therefor
GB0401020D0 (en) Time panels
GB0505908D0 (en) Antibodies and their use in therapy
GB0507219D0 (en) Antibody and uses thereof
GB0507272D0 (en) Antibody and uses thereof
ZA200705716B (en) IRTA-2 antibodies and their uses

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20141208